Peptide ReadinessJoin the beta
Back to database

FDA 2027 COMPOUNDING REVIEW

LL-37

A forward regulatory signal before a final committee evidence package and decision.

Record version 1.0Last verified 5 September 2026Evidence grade DRegulatory surveillance cohort
FDA STATUS

Not FDA approved for marketed wellness uses; committee consideration is not approval

MHRA / UK LICENCE

No UK marketing authorisation identified

NICE STATUS

No NICE recommendation identified

NHS ACCESS

No routine NHS access

PRIVATE LAWFUL USE CONTEXT

Research market presence is not licensed clinical use

EVIDENCE MATURITY

Research interest with material safety and formulation questions

DEVELOPMENT PHASE

Regulatory surveillance cohort

MARKET EXPOSURE

Emerging

PROFESSIONAL RELEVANCE

Create an evidence dossier and update the record when FDA briefing materials and votes are published.

Product, formulation and indication

No authorised product is represented for this investigational or surveillance record. Product level data will be added only when a sourceable regulated product exists.

Status history

Production baseline verification recorded.

Listed for forthcoming FDA PCAC consideration

Future material changes will be appended with their previous status and source; they will not be silently overwritten.

Verify this record

Source labels identify what each link can prove. Sponsor material is used for time sensitive development claims only.